Couple of things to throw out there:<p>1) If you are able to bring a major drug to market 3 months earlier, it's worth billions. Hence the continued interest in computational approaches.<p>2) Salaries in the pharma/biotech biz are set nationally. Yeah, there are variations by geography, but less than one would expect. Thus, a PhD with x years can look up the salary range per region, etc.<p>3) The data is confusing and the error range(s) are unknown. So, many/most of the models are retrospective rather than prospective and if the initial guess at the biological target or model fails, everything else is a waste of time. Google for all of the failures re: Alzheimers.<p>3b) As we can't test on humans (at least not ethically), we're totally dependent on animal models being good predictors of human behaviour. But, while chimps are like 98% similar to humans, the difference has resulted in catastrophic failures in Phase 1 testing. Diseases by the score have been cured in mice...<p>4) Computational modelling occurs at the start of the process, which is the most efficient. I think they had a sequence for the mRNA vaccine a few days after the Chinese published the data. Getting it made, stable and deliverable is where the time was consumed. And then the various clinical trials are significant costs in time and money. Hard to trust a model for a new class of disease or mechanism.<p>5) Computational methodology has been (over)sold since the 60's. Yeah, there have been successes but they've been way fewer than hoped and people have grown rather jaded when presented with the latest breakthrough. ML/AI isn't really new as it was studied in the 90's, but there's way more data. See (3) above.<p>6) The crystal doesn't always form. The reaction yields brown oil rather than white powder, or doesn't scale. Chemistry is messy. And there's a lot of material design problems that have not been amenable to modelling. There are new ways of gathering information (CryoEM), but we still need more/better.<p>7) We need newer software and better parameterization. Both of these trace back to academic work on Vaxen, maybe SGI's. Visualization software is probably the most valuable tool right now, with broad acceptance in the research stage.<p>7b) Physics might bite us in the ass. MD software, for example, tries to model explicit protein, ligand and solvent atoms/molecules. Even given revised software and parameterization, entropy or chaos might prevent accurate numbers or what we can calculate might not be pertinent.<p>I could go on (and on), but I wanted to leave you with an upside... If anybody DOES deliver the goods, they'll be bloody heroes. Fame, fortune, the whole gig - like CRISPR and the other advances that have occurred. So, if you and your buddies are smart and dedicated, it'll beat the snot out of selling ads on handhelds in terms of making a difference.